Although collectively dermatologists are doing more, each dermatologist may be doing less in the higher quintiles.
There are two pathways that lead to atopic dermatitis. Their origins differ, but they both impair the immune system and skin barrier in AD.
Long-term data for dupilumab in atopic dermatitis revealed at the American Academy of Dermatology (AAD) 75th Annual Meeting reflect safety, rapid relief of troublesome symptoms and a long-lived response in keeping with the drug’s breakthrough status, experts told Dermatology Times.
PDT is underutilized as field treatment for AKs. An expert pushes for two to three hours' incubation time in her clinic and suggests efficacy-elevating pretreatment of lesions.
Being able to predict which patients will respond to which treatments will help dermatologists in treating psoriasis, preventing progression to psoriatic arthritis and reducing comorbidities.
Taking the sting and stress out of dermatologic procedures requires low-tech distraction techniques and, often in the case of children, amusing apps.
CMS' meaningful use program for electronic health records (EHRs) has morphed into the Advancing Care Information (ACI) initiative, which loosens restrictions for earning EHR bonuses.
A recent pediatric allergy study spells out how to safely introduce peanuts to high-risk (and other) children. Another study suggests that melatonin may have immunomodulatory effects in AD.
Promising new treatments recently approved or under development for atopic dermatitis include crisaborole, JAK inhibitors and dupilumab, an expert said.
Important recent publications from mainstream medical journals highlight the following: Automobile side windows do not block UV radiation well; An adjuvant herpes zoster vaccine works as well in patients over 70 years old as it did in the 50-plus age group; The American Academy of Ophthalmology recommends hydroxychloroquine and chloroquine dosing based on actual, not ideal, weight.